This study intended to elucidate the potential of FRAX486 as a reversal agent for multidrug resistance mediated by ABCB1, as well as its therapeutic potential in overcoming drug resistance and improving cancer patient treatment outcomes. This evidence concerns the gene ABCB1 and cancer.